244
Participants
Start Date
August 20, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Secukinumab
Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
Ixekizumab
Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
Brodalumab
Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
Guselkumab
Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
Risankizumab
Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
Tildrakizumab
Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
Bimekizumab
Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
Ghent University Hospital, Ghent
ULB Erasme, Brussels
AZ Maria Middelares, Ghent
AZ St Lucas, Ghent
UCL Saint Luc, Leuven
UZ Leuven, Leuven
CHU Liege, Liège
Dermatologie Maldegem, Maldegem
Ziekenhuisgroep Twente, Almelo
Bravis hospital, Bergen op Zoom
Amphia Hospital, Breda
Slingeland hospital, Doetinchem
Catharina hospital, Eindhoven
UMC Groningen, Groningen
Maastricht UMC, Maastricht
Erasmus MC, Rotterdam
UMC Utrecht, Utrecht
Máxima Medisch Centrum, Veldhoven
Radboudumc, Nijmegen
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Belgium Health Care Knowledge Centre
OTHER_GOV
University Hospital, Ghent
OTHER
Radboud University Medical Center
OTHER